Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

1.

Primary biliary cirrhosis and bile acids.

Corpechot C.

Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S13-20. doi: 10.1016/S2210-7401(12)70016-5. Review.

PMID:
23141888
[PubMed - indexed for MEDLINE]
2.

Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.

Poupon R.

Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S3-12. doi: 10.1016/S2210-7401(12)70015-3. Review.

PMID:
23141891
[PubMed - indexed for MEDLINE]
3.

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.

Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, Saito Y, Takikawa H, Imawari M, Matsuzaki Y.

Hepatology. 2013 May;57(5):1931-41. doi: 10.1002/hep.26018. Epub 2013 Apr 5.

PMID:
22911624
[PubMed - indexed for MEDLINE]
4.

[Treatment of cholestatic liver diseases].

Gatzen M, Pausch J.

Med Klin (Munich). 2002 Mar 15;97(3):152-9. Review. German.

PMID:
11957790
[PubMed - indexed for MEDLINE]
5.

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.

Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, Ackermann H, Happ J, Leuschner U.

Gastroenterology. 1999 Oct;117(4):918-25.

PMID:
10500075
[PubMed - indexed for MEDLINE]
6.

Fenofibrate for patients with asymptomatic primary biliary cirrhosis.

Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K.

World J Gastroenterol. 2004 Mar 15;10(6):894-8.

PMID:
15040040
[PubMed - indexed for MEDLINE]
Free Article
7.

Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.

Färkkilä M, Rautiainen H, Kärkkäinen P, Karvonen AL, Nurmi H, Niemelä O.

Liver Int. 2008 Jul;28(6):787-97. doi: 10.1111/j.1478-3231.2008.01722.x.

PMID:
18397236
[PubMed - indexed for MEDLINE]
8.

Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.

Silveira MG, Lindor KD.

Clin Liver Dis. 2008 May;12(2):425-43; x-xi. doi: 10.1016/j.cld.2008.02.008. Review.

PMID:
18456189
[PubMed - indexed for MEDLINE]
9.

Bile acid therapy and markers of immune-mediated damage in primary biliary cirrhosis.

de Caestecker JS.

Eur J Gastroenterol Hepatol. 1997 Feb;9(2):145-7.

PMID:
9058624
[PubMed - indexed for MEDLINE]
10.

Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.

Hazzan R, Tur-Kaspa R.

J Clin Gastroenterol. 2010 May-Jun;44(5):371-3. doi: 10.1097/MCG.0b013e3181c115b3.

PMID:
19881358
[PubMed - indexed for MEDLINE]
11.

Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study.

Eriksson LS, Olsson R, Glauman H, Prytz H, Befrits R, Rydén BO, Einarsson K, Lindgren S, Wallerstedt S, Wedén M.

Scand J Gastroenterol. 1997 Feb;32(2):179-86.

PMID:
9051880
[PubMed - indexed for MEDLINE]
12.

[Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].

Olsson R.

Lakartidningen. 2002 Mar 21;99(12):1325-30. Review. Swedish.

PMID:
11998165
[PubMed - indexed for MEDLINE]
13.

Primary biliary cirrhosis.

Rinella ME.

Ann Hepatol. 2006 Jul-Sep;5(3):198-200.

PMID:
17060882
[PubMed - indexed for MEDLINE]
14.

Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.

Dilger K, Hohenester S, Winkler-Budenhofer U, Bastiaansen BA, Schaap FG, Rust C, Beuers U.

J Hepatol. 2012 Jul;57(1):133-40. doi: 10.1016/j.jhep.2012.02.014. Epub 2012 Mar 10. Erratum in: J Hepatol. 2014 Mar;60(3):684.

PMID:
22414767
[PubMed - indexed for MEDLINE]
15.

[The influence of ursodeoxycholic acid on some biochemical, immunologic and histopathologic parameters in patients with primary biliary cirrhosis].

Skulina D, Owczarek D, Ciećko-Michalska I, Szczepański W, Tetnowski J, Garlicka M, Janas-Skulina U.

Przegl Lek. 1999;56(3):201-4. Polish.

PMID:
10442009
[PubMed - indexed for MEDLINE]
16.

Chronic cholestatic diseases.

Poupon R, Chazouillères O, Poupon RE.

J Hepatol. 2000;32(1 Suppl):129-40. Review.

PMID:
10728800
[PubMed - indexed for MEDLINE]
17.

Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.

Silveira MG, Lindor KD.

Expert Opin Pharmacother. 2014 Feb;15(3):365-72. doi: 10.1517/14656566.2014.873404. Epub 2014 Jan 2.

PMID:
24382005
[PubMed - in process]
18.

An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis.

Neuman MG, Cameron RG, Haber JA, Katz GG, Blendis LM.

Liver. 2002 Jun;22(3):235-44.

PMID:
12100574
[PubMed - indexed for MEDLINE]
19.

Bezafibrate treatment: a new medical approach for PBC patients?

Kanda T, Yokosuka O, Imazeki F, Saisho H.

J Gastroenterol. 2003;38(6):573-8.

PMID:
12825134
[PubMed - indexed for MEDLINE]
20.

Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.

Lirussi F, Okolicsanyi L.

Ital J Gastroenterol. 1992 Jan;24(1):31-5. Review.

PMID:
1571577
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk